These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1102 related items for PubMed ID: 25404086

  • 1. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
    Rivelli RF, Gonçalves RT, Leite M, Santos MA, Delgado AG, Cardoso LR, Takiya CM.
    Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
    [Abstract] [Full Text] [Related]

  • 2. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
    de Sandes-Freitas TV, Felipe CR, Campos ÉF, de Lima MG, Soares MF, de Franco MF, Aguiar WF, Tedesco-Silva H, Medina-Pestana JO.
    Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
    [Abstract] [Full Text] [Related]

  • 3. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 4. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
    Burkhalter F, Oettl T, Descoeudres B, Bachmann A, Guerke L, Mihatsch MJ, Dickenmann M, Steiger J.
    Transplant Proc; 2012 Dec; 44(10):2961-5. PubMed ID: 23195006
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Molecular and structural consequences of early renal allograft injury.
    Baboolal K, Jones GA, Janezic A, Griffiths DR, Jurewicz WA.
    Kidney Int; 2002 Feb; 61(2):686-96. PubMed ID: 11849412
    [Abstract] [Full Text] [Related]

  • 7. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK, Wu FL, Lai IR, Lee CY, Hu RH, Lee PH.
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [Abstract] [Full Text] [Related]

  • 8. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 9. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial.
    Weir MR, Pearson TC, Patel A, Peddi VR, Kalil R, Scandling J, Chan L, Baliga P, Melton L, Mulgaonkar S, Waid T, Schaefer H, Youssef N, Anandagoda L, McCollum D, Lawson S, Gordon R.
    Transplantation; 2017 Jan 27; 101(1):157-165. PubMed ID: 26950714
    [Abstract] [Full Text] [Related]

  • 10. Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction.
    Paoletti E, Ratto E, Bellino D, Marsano L, Cassottana P, Cannella G.
    J Nephrol; 2012 Jan 27; 25(5):709-18. PubMed ID: 22038336
    [Abstract] [Full Text] [Related]

  • 11. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
    Cotovio P, Neves M, Santos L, Macário F, Alves R, Mota A.
    Transplant Proc; 2012 Dec 27; 44(10):2966-70. PubMed ID: 23195007
    [Abstract] [Full Text] [Related]

  • 12. Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure to calcineurin inhibitors.
    Yu JH, Kim KW, Kim BM, Chung BH, Cho ML, Choi BS, Park CW, Kim YS, Yang CW.
    Korean J Intern Med; 2016 May 27; 31(3):552-9. PubMed ID: 26968190
    [Abstract] [Full Text] [Related]

  • 13. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
    Knight RJ, Podder H, Kerman RH, Lawless A, Katz SM, Van Buren CT, Gaber AO, Kahan BD.
    Transplantation; 2010 Mar 27; 89(6):727-32. PubMed ID: 20195219
    [Abstract] [Full Text] [Related]

  • 14. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
    Nankivell BJ, PʼNg CH, OʼConnell PJ, Chapman JR.
    Transplantation; 2016 Aug 27; 100(8):1723-31. PubMed ID: 27306529
    [Abstract] [Full Text] [Related]

  • 15. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov 27; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 16. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B, Höcker B.
    Pediatr Transplant; 2006 Sep 27; 10(6):721-9. PubMed ID: 16911497
    [Abstract] [Full Text] [Related]

  • 17. Steroid or tacrolimus withdrawal in renal transplant recipients using sirolimus.
    de Sandes Freitas TV, Harada KM, Felipe CR, Galante NZ, Sampaio EL, Ikehara E, Alfieri F, Tedesco-Silva Júnior H, Medina-Pestana JO.
    Int Urol Nephrol; 2011 Dec 27; 43(4):1221-8. PubMed ID: 21761129
    [Abstract] [Full Text] [Related]

  • 18. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ, Felipe CR, Tedesco-Silva H, Osmar Medina-Pestana J.
    Pharmacotherapy; 2016 Feb 27; 36(2):152-65. PubMed ID: 26799522
    [Abstract] [Full Text] [Related]

  • 19. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Chhabra D, Skaro AI, Leventhal JR, Dalal P, Shah G, Wang E, Gallon L.
    Clin J Am Soc Nephrol; 2012 Mar 27; 7(3):504-12. PubMed ID: 22282478
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK, Huh KH, Ha J, Kim YH, Kim YL, Kim YS.
    Transplantation; 2015 Jan 27; 99(1):180-6. PubMed ID: 24983307
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.